Cargando…
Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice
Muscle repair in dysferlinopathies is defective. Although macrophage (Mø)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mø a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675822/ https://www.ncbi.nlm.nih.gov/pubmed/36402750 http://dx.doi.org/10.1038/s41419-022-05416-1 |
_version_ | 1784833455696117760 |
---|---|
author | Farini, A. Tripodi, L. Villa, C. Napolitano, F. Strati, F. Molinaro, D. Facciotti, F. Cassani, B. Torrente, Y. |
author_facet | Farini, A. Tripodi, L. Villa, C. Napolitano, F. Strati, F. Molinaro, D. Facciotti, F. Cassani, B. Torrente, Y. |
author_sort | Farini, A. |
collection | PubMed |
description | Muscle repair in dysferlinopathies is defective. Although macrophage (Mø)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mø and effector T cells are increased in muscle of dysferlin-deficient BlAJ mice. In addition, symptomatic BlAJ mice have increased muscle production of immunoproteasome. In vitro analyses using bone marrow-derived Mø of BlAJ mice show that immunoproteasome inhibition results in C3aR1 and C5aR1 downregulation and upregulation of M2-associated signaling. Administration of immunoproteasome inhibitor ONX-0914 to BlAJ mice rescues muscle function by reducing muscle infiltrates and fibro-adipogenesis. These findings reveal an important role of immunoproteasome in the progression of muscular dystrophy in BlAJ mouse and suggest that inhibition of immunoproteasome may produce therapeutic benefit in dysferlinopathy. |
format | Online Article Text |
id | pubmed-9675822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96758222022-11-21 Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice Farini, A. Tripodi, L. Villa, C. Napolitano, F. Strati, F. Molinaro, D. Facciotti, F. Cassani, B. Torrente, Y. Cell Death Dis Article Muscle repair in dysferlinopathies is defective. Although macrophage (Mø)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mø and effector T cells are increased in muscle of dysferlin-deficient BlAJ mice. In addition, symptomatic BlAJ mice have increased muscle production of immunoproteasome. In vitro analyses using bone marrow-derived Mø of BlAJ mice show that immunoproteasome inhibition results in C3aR1 and C5aR1 downregulation and upregulation of M2-associated signaling. Administration of immunoproteasome inhibitor ONX-0914 to BlAJ mice rescues muscle function by reducing muscle infiltrates and fibro-adipogenesis. These findings reveal an important role of immunoproteasome in the progression of muscular dystrophy in BlAJ mouse and suggest that inhibition of immunoproteasome may produce therapeutic benefit in dysferlinopathy. Nature Publishing Group UK 2022-11-19 /pmc/articles/PMC9675822/ /pubmed/36402750 http://dx.doi.org/10.1038/s41419-022-05416-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Farini, A. Tripodi, L. Villa, C. Napolitano, F. Strati, F. Molinaro, D. Facciotti, F. Cassani, B. Torrente, Y. Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice |
title | Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice |
title_full | Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice |
title_fullStr | Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice |
title_full_unstemmed | Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice |
title_short | Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice |
title_sort | inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient blaj mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675822/ https://www.ncbi.nlm.nih.gov/pubmed/36402750 http://dx.doi.org/10.1038/s41419-022-05416-1 |
work_keys_str_mv | AT farinia inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT tripodil inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT villac inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT napolitanof inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT stratif inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT molinarod inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT facciottif inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT cassanib inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice AT torrentey inhibitionoftheimmunoproteasomemodulatesinnateimmunitytoamelioratemusclepathologyofdysferlindeficientblajmice |